Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study

Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet, Clarisse Audigier-Valette, Lionel Falchero, Alain Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, Stéphane Hominal, Chrystèle Locher, Romain Corre, Christos Chouaid, Charles Ricordel, Hervé LENA, Alain VERGNENEGRE, Chrystèle LOCHER, Margaux GEIER, Thomas PASCAL, Laurent GREILLIER, Pierre FOURNEL, Maurice PEROL, Lionel FALCHERO, Stéphanie MARTINEZ, Nicolas PALEIRON, Florian GUISIER, Gwenaëlle LE GARFF, Hélène DOUBRE, Stéphane HOMINAL, Jean-Bernard AULIAC, Marie WISLEZ, Gonzague DE CHABOT, Pierre-Alexandre HAUSS, Isabelle MONNET, Pascal ASSOULINE, Cécile DUJON, Hervé LE FLOCH, Pierre DEMONTROND, Régine LAMY, Géraldine FRANCOIS, Marie MARCQ, Clarisse AUDIGIER-VALETTE, Anne MADROSZYK-FLANDIN, Jacky CREQUIT, Roland SCHOTT, Samir ABDICHE, Marielle SABATINI, Thierry CHATELLIER, Romain CORRE, Jacques LE TREUT

Open source

DOI
10.1016/s2213-2600(24)00264-9
Published
2025-02
Container
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-24-00264-9,
  title = {Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study},
  author = {Hervé Léna and Laurent Greillier and Claire Cropet and Olivier Bylicki and Isabelle Monnet and Clarisse Audigier-Valette and Lionel Falchero and Alain Vergnenègre and Pierre Demontrond and Margaux Geier and Florian Guisier and Stéphane Hominal and Chrystèle Locher and Romain Corre and Christos Chouaid and Charles Ricordel and Hervé LENA and Alain VERGNENEGRE and Chrystèle LOCHER and Margaux GEIER and Thomas PASCAL and Laurent GREILLIER and Pierre FOURNEL and Maurice PEROL and Lionel FALCHERO and Stéphanie MARTINEZ and Nicolas PALEIRON and Florian GUISIER and Gwenaëlle LE GARFF and Hélène DOUBRE and Stéphane HOMINAL and Jean-Bernard AULIAC and Marie WISLEZ and Gonzague DE CHABOT and Pierre-Alexandre HAUSS and Isabelle MONNET and Pascal ASSOULINE and Cécile DUJON and Hervé LE FLOCH and Pierre DEMONTROND and Régine LAMY and Géraldine FRANCOIS and Marie MARCQ and Clarisse AUDIGIER-VALETTE and Anne MADROSZYK-FLANDIN and Jacky CREQUIT and Roland SCHOTT and Samir ABDICHE and Marielle SABATINI and Thierry CHATELLIER and Romain CORRE and Jacques LE TREUT},
  year = {2025},
  journal = {The Lancet Respiratory Medicine},
  doi = {10.1016/s2213-2600(24)00264-9},
  url = {https://doi.org/10.1016/s2213-2600(24)00264-9}
}

RIS

TY  - JOUR
TI  - Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
AU  - Hervé Léna
AU  - Laurent Greillier
AU  - Claire Cropet
AU  - Olivier Bylicki
AU  - Isabelle Monnet
AU  - Clarisse Audigier-Valette
AU  - Lionel Falchero
AU  - Alain Vergnenègre
AU  - Pierre Demontrond
AU  - Margaux Geier
AU  - Florian Guisier
AU  - Stéphane Hominal
AU  - Chrystèle Locher
AU  - Romain Corre
AU  - Christos Chouaid
AU  - Charles Ricordel
AU  - Hervé LENA
AU  - Alain VERGNENEGRE
AU  - Chrystèle LOCHER
AU  - Margaux GEIER
AU  - Thomas PASCAL
AU  - Laurent GREILLIER
AU  - Pierre FOURNEL
AU  - Maurice PEROL
AU  - Lionel FALCHERO
AU  - Stéphanie MARTINEZ
AU  - Nicolas PALEIRON
AU  - Florian GUISIER
AU  - Gwenaëlle LE GARFF
AU  - Hélène DOUBRE
AU  - Stéphane HOMINAL
AU  - Jean-Bernard AULIAC
AU  - Marie WISLEZ
AU  - Gonzague DE CHABOT
AU  - Pierre-Alexandre HAUSS
AU  - Isabelle MONNET
AU  - Pascal ASSOULINE
AU  - Cécile DUJON
AU  - Hervé LE FLOCH
AU  - Pierre DEMONTROND
AU  - Régine LAMY
AU  - Géraldine FRANCOIS
AU  - Marie MARCQ
AU  - Clarisse AUDIGIER-VALETTE
AU  - Anne MADROSZYK-FLANDIN
AU  - Jacky CREQUIT
AU  - Roland SCHOTT
AU  - Samir ABDICHE
AU  - Marielle SABATINI
AU  - Thierry CHATELLIER
AU  - Romain CORRE
AU  - Jacques LE TREUT
PY  - 2025
JO  - The Lancet Respiratory Medicine
DO  - 10.1016/s2213-2600(24)00264-9
UR  - https://doi.org/10.1016/s2213-2600(24)00264-9
ER  -

APA

Léna, H., Greillier, L., Cropet, C., Bylicki, O., Monnet, I., Audigier-Valette, C., Falchero, L., Vergnenègre, A., Demontrond, P., Geier, M., Guisier, F., Hominal, S., Locher, C., Corre, R., Chouaid, C., Ricordel, C., LENA, H., VERGNENEGRE, A., LOCHER, C., GEIER, M., PASCAL, T., GREILLIER, L., FOURNEL, P., PEROL, M., FALCHERO, L., MARTINEZ, S., PALEIRON, N., GUISIER, F., GARFF, G. L., DOUBRE, H., HOMINAL, S., AULIAC, J., WISLEZ, M., CHABOT, G. D., HAUSS, P., MONNET, I., ASSOULINE, P., DUJON, C., FLOCH, H. L., DEMONTROND, P., LAMY, R., FRANCOIS, G., MARCQ, M., AUDIGIER-VALETTE, C., MADROSZYK-FLANDIN, A., CREQUIT, J., SCHOTT, R., ABDICHE, S., SABATINI, M., CHATELLIER, T., CORRE, R., & TREUT, J. L. (2025). Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00264-9

Source records